Efficacy of Olanzapine in Anxiety Dimension of Schizophrenia: A Systematic Review of Randomized Controlled Trials

키워드

참고문헌 (68)

1. Yoshio Kaneko, "Cognitive Remediation in Schizophrenia", Clinical Psychopharmacology and Neuroscience, 10(3), pp.125~135 (2012), 대한정신약물학회
2. Jung-Jin Kim, "Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia", Clinical Psychopharmacology and Neuroscience, 19(4), pp.600~609 (2021), 대한정신약물학회[DOI]
3. Harshit Garg, "New Onset Obsessive Compulsive Disorder Following High Frequency Repetitive Transcranial Magnetic Stimulation over Left Dorsolateral Prefrontal Cortex for Treatment of Negative Symptoms in a Patient with Schizophrenia", Clinical Psychopharmacology and Neuroscience, 17(3), pp.443~445 (2019), 대한정신약물학회[DOI]
4. Pincus HA, "Psychiatric comorbidity : is more less?", World Psychiatry, 3, pp.18~23 (2004)
5. Temmingh H, "Anxiety in patients with schizophrenia : epidemiology and management", CNS Drugs, 29, pp.819~832 (2015)
6. Tien AY, "Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome", Arch Gen Psychiatry, 49, pp.37~46 (1992)
7. Howells FM, "Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia : structured review", Hum Psychopharmacol, 32, pp.e2628~ (2017)
8. Podea DM, "A fresh look at anxiety disorders", pp.131~144 (2015), IntechOpen
9. Braga RJ, "Anxiety comorbidity in schizophrenia", Psychiatry Res, 210, pp.1~7 (2013)
10. Craig T, "Obsessive-compulsive and panic symptoms in patients with first-admission psychosis", Am J Psychiatry, 159, pp.592~598 (2002)
11. Lysaker PH, "Anxiety symptoms in schizophrenia spectrum disorders : associations with social function, positive and negative symptoms, hope and trauma history", Acta Psychiatr Scand, 116, pp.290~298 (2007)
12. Stefanopoulou E, "Insight, global functioning and psychopathology amongst in-patient clients with schizophrenia", Psychiatr Q, 80, pp.155~165 (2009)
13. Wiffen BD, "Correlates, change and ‘state or trait’ properties of insight in schizophrenia", Schizophr Res, 122, pp.94~103 (2010)
14. GoffDC, "Augmentation strategies in the treatment of schizophrenia", CNS Spectr, 6, pp.904~ (2001)
15. Ritsner MS, "L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder : an 8-week, randomized, double-blind, placebocontrolled, 2-center study", J Clin Psychiatry, 72, pp.34~42 (2011)
16. Blessing EM, "Cannabidiol as a potential treatment for anxiety disorders", Neurotherapeutics, 12, pp.825~836 (2015)
17. Englisch S, "Augmentation with pregabalin in schizophrenia", J Clin Psychopharmacol, 30, pp.437~440 (2010)
18. Buckley PF, "Psychiatric comorbidities and schizophrenia", Schizophr Bull, 35, pp.383~402 (2009)
19. Novick D, "Real-world effectiveness of antipsychotics for the treatment of negative symptoms in patients with schizophrenia with predominantly negative symptoms", Pharmacopsychiatry, 50, pp.56~63 (2017)
20. Littrell KH, "The effect of olanzapine on anxiety among patients with schizophrenia : preliminary findings", J Clin Psychopharmacol, 23, pp.523~525 (2003)
21. Mauri MC, "A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia", Clin Neuropharmacol, 29, pp.126~131 (2006)
22. Methley AM, "PICO, PICOS and SPIDER : a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews", BMC Health Serv Res, 14, pp.579~ (2014)
23. Sirota P, "Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia", Hum Psychopharmacol, 21, pp.227~234 (2006)
24. Tollefson GD, "Anxious-depressive symptoms in schizophrenia : a new treatment target for pharmacotherapy", Schizophr Res, 35(Suppl), pp.S13~S21 (1999)
25. Dossenbach M, "Olanzapine versus fluphenazine-6weeks treatment of anxiety symptoms during acute schizophrenia", Schizophr Res, 29, pp.203~ (1998)
26. Hofer A, "Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine", Pharmacopsychiatry, 40, pp.1~8 (2007)
27. Rasmussen SA, "The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis : haloperidol versus olanzapine", Psychiatry Res, 241, pp.72~77 (2016)
28. Sacchetti E, "A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia : the QUERISOLA trial", Schizophr Res, 98, pp.55~65 (2008)
29. Strous RD, "Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia : a naturalistic prospective 12-week observational study", Hum Psychopharmacol, 21, pp.235~243 (2006)
30. Page MJ, "The PRISMA 2020 statement : an updated guideline for reporting systematic reviews", BMJ, 372, pp.n71~ (2021)
31. Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
32. Beasley CM Jr, "Olanzapine versus placebo and haloperidol : acute phase results of the North American double-blind olanzapine trial", Neuropsychopharmacology, 14, pp.111~123 (1996)
33. Beasley CM Jr, "Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial", Psychopharmacology(Berl), 124, pp.159~167 (1996)
34. Beasley CM Jr, "Olanzapine versus haloperidol : acute phase results of the international double-blind olanzapine trial", Eur Neuropsychopharmacol, 7, pp.125~137 (1997)
35. Tollefson GD, "Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders : results of an international collaborative trial", Am J Psychiatry, 154, pp.457~465 (1997)
36. Davis JM, "The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis : combined results of the North American and international trials", J Clin Psychiatry, 62, pp.757~771 (2001)
37. Ascher-Svanum H, "Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia", BMC Psychiatry, 5, pp.3~ (2005)
38. Tollefson GD, "A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia", Biol Psychiatry, 43, pp.803~810 (1998)
39. Volavka J, "Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder", Am J Psychiatry, 159, pp.255~262 (2002)
40. Lindenmayer JP, "Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia", J Clin Psychiatry, 65, pp.551~556 (2004)
41. Wang X, "Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy : a switch study", J Psychiatr Res, 40, pp.669~676 (2006)
42. Conley RR, "A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder", Am J Psychiatry, 158, pp.765~774 (2001)
43. Jeste DV, "International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia", Am J Geriatr Psychiatry, 11, pp.638~647 (2003)
44. Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
45. Crapanzano C, "Quetiapine in the anxiety dimension of mood disorders : a systematic review of the literature to support clinical practice", J Clin Psychopharmacol, 41, pp.436~449 (2021)
46. Bhana N, "Olanzapine : an updated review of its use in the management of schizophrenia", Drugs, 61, pp.111~161 (2001)
47. Bymaster FP, "Radioreceptor binding profile of the atypical antipsychotic olanzapine", Neuropsychopharmacology, 14, pp.87~96 (1996)
48. Crapanzano C, "Olanzapine for the treatment of somatic symptom disorder : biobehavioral processes and clinical implications", Psychosom Med, 84, pp.393~395 (2022)
49. Crapanzano C, "Clothiapine : highlights on pharmacological and clinical profile of an undervalued drug", Swiss Arch Neurol Psychiatry Psychother, 173, pp.w10065~ (2022)
50. Crapanzano C, "Clinical perspective on antipsychotic receptor binding affinities", Braz J Psychiatry, 43, pp.680~681 (2021)
51. Cohen H, "Anxiolytic effect and memory improvement in rats by antisense oligodeoxynucleotide to 5-hydroxytryptamine-2A precursor protein", Depress Anxiety, 22, pp.84~93 (2005)
52. Craige CP, "Dorsal raphe 5-HT(2C)receptor and GABA networks regulate anxiety produced by cocaine withdrawal", Neuropharmacology, 93, pp.41~51 (2015)
53. Serafim KR, "H1 but not H2 histamine antagonist receptors mediate anxiety-related behaviors and emotional memory deficit in mice subjected to elevated plus-maze testing", Braz J Med Biol Res, 46, pp.440~446 (2013)
54. Okuyama S, "Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor", Brain Res, 821, pp.150~159 (1999)
55. Sema Ketenci, "The Neurochemical Effects of Prazosin Treatment on Fear Circuitry in a Rat Traumatic Stress Model", Clinical Psychopharmacology and Neuroscience, 18(2), pp.219~230 (2020), 대한정신약물학회[DOI]
56. Wall PM, "Infralimbic muscarinic M1 receptors modulate anxiety-like behaviour and spontaneous working memory in mice", Psychopharmacology(Berl), 155, pp.58~68 (2001)
57. Javitt DC, "Glutamate as a therapeutic target in psychiatric disorders", Mol Psychiatry, 9, pp.984~997 (2004)
58. Chang Y, "Neurosteroid allopregnanolone inhibits glutamate release from rat cerebrocortical nerve terminals", Synapse, 73, pp.e22076~ (2019)
59. Mead A, "Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms : contrast with haloperidol and chlordiazepoxide", Pharmacol Biochem Behav, 90, pp.551~562 (2008)
60. Sacchi S, "Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity", Sci Rep, 7, pp.46288~ (2017)
61. Tarazi FI, "Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types : implications for antipsychotic drug treatment", J Pharmacol Exp Ther, 306, pp.1145~1151 (2003)
62. Kiran C, "Prevalence of comorbid anxiety disorders in schizophrenia", Ind Psychiatry J, 25, pp.35~40 (2016)
63. Davies N, "Which characteristics of schizophrenia predate psychosis?", J Psychiatr Res, 32, pp.121~131 (1998)
64. Ohi K, "Shared genetic etiology between anxiety disorders and psychiatric and related intermediate phenotypes", Psychol Med, 50, pp.692~704 (2020)
65. Pringsheim T, "The assessment and treatment of antipsychotic-induced akathisia", Can J Psychiatry, 63, pp.719~729 (2018)
66. Grillo L, "A possible link between anxiety and schizophrenia and a possible role of anhedonia", Schizophr Res Treatment, 2018, pp.5917475~ (2018)
67. Carter DM, "Patients’ strategies for coping with auditory hallucinations", J Nerv Ment Dis, 184, pp.159~164 (1996)
68. Gentil V, "Why anguish?", J Psychopharmacol, 25, pp.146~147 (2011)

관련 논문AI추천